论文部分内容阅读
目的：探讨小剂量厄贝沙坦、福辛普利联用治疗扩张型心肌病(dilated cadiomyopathy, DCM)的临床疗效和安全性。方法99例DCM患者在利尿剂、β-受体阻滞剂,洋地黄治疗基础上,随机分为3组,治疗前后分别检测左右室舒张末期内径(LVEDD/RVEDD)/左室射血分数(LVEF)、6 min步行实验(6-MWT)、血压、血钾及血肌酐水平。结果通过治疗前后,对A组、B组和C组在左室舒张末期内径、右室舒张末期内径、左室射血分数、6 min步行距离上述4项指标进行比较,均较治疗前后差异有统计学意义(P<0.05),且C组更明显,而A组与B组比较差异无统计学意义(P<0.05)；而治疗前后A、B、C 3组在收缩压、舒张压、血肌酐、血钾等指标方面差异无统计学意义(P<0.05)。结论小剂量厄贝沙坦、福辛普利联用治疗DCM可明显改善心功能,逆转心室重构,疗效优于单用常规剂量治疗,并且安全性好。“,”Objective To study the clinic therapeutic effect and safty of low dose of Fosinopril combined with Ibasartan in the treatment of dilate cadiomyopathy(DCM). Methods 99 cases of DCM patients on diuretics, beta blockers, digitalis therapy, were randomly divided into 3 groups, before and after treatment were detected in left ventricular end diastolic diameter (LVEDD/RVEDD) and left ventricular ejection fraction (LVEF), 6min walking test (6-MWT), blood pressure, serum potassium and serum creatinine level. Results Before and after 12 months treatment , compare with the end-diastolic diameter of left ventricular(LVEDD), end-diastolic diameter of right ventricle (RVEDD), the left ventricular ejection fraction(LVEF)and six-minutes-walk trial (6-MWT), the changes were significantly different than before in three groups A,B and C(P<0.05), but in C groups, the changes mentioned above were significantly. Compared with the levels of systolic blood pressure(SBP),the diastolic kalium in plasma, there of blood pressure(DBP), cretinine in plasma, the levels of kalium in plasma,there was no statistics variance before and after treatment in each other groups.(P<0.05). Conclusion The effect of low dose fosinopril and ibasartan combinion on DCM is better than alone routine dose fosinopril or ibasartan treatment in improving level of heart function and remodeling of left ventricle , and it is safe.